Citius Pharmaceuticals reports first revenue of $3.9 mln

Reuters

02/13

Citius Pharmaceuticals reports first revenue of $3.9 mln

Overview

Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026
Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38
Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025

Outlook

Citius anticipates growth from international market expansion and oncology franchise development
Company plans to expand LYMPHIR access in Europe and the Middle East
Citius focuses on technology-driven platform to enhance market penetration

Result Drivers

LYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025
AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetration
INTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient Programs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$8.20 mln
Q1 Basic EPS		-$0.38

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79
The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nPn7wjdcta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2611054152"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611054152\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611054152?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611054152","market":"us","top_or_hot":-1,"title":"Citius Pharmaceuticals reports first revenue of $3.9 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Citius Pharmaceuticals reports first revenue of $3.9 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026</p></li><li><p>Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38</p></li><li><p><a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> launched LYMPHIR for cutaneous T-cell lymphoma in December 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Citius anticipates growth from international market expansion and oncology franchise development</p></li><li><p>Company plans to expand LYMPHIR access in Europe and the Middle East</p></li><li><p>Citius focuses on technology-driven platform to enhance market penetration</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025</p></li><li><p>AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetration</p></li><li><p>INTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient Programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 Net Income</p></td><td></td><td><p>-$8.20 mln</p></td><td></td></tr><tr><td><p>Q1 Basic EPS</p></td><td></td><td><p>-$0.38</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79</p></li><li><p>The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months ago</p></li></ul><p>Press Release: <span>ID:nPn7wjdcta</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Pharmaceuticals reports first revenue of $3.9 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Pharmaceuticals reports first revenue of $3.9 mln\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-13 21:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Citius Pharmaceuticals reports first revenue of $3.9 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026</p></li><li><p>Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38</p></li><li><p><a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> launched LYMPHIR for cutaneous T-cell lymphoma in December 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Citius anticipates growth from international market expansion and oncology franchise development</p></li><li><p>Company plans to expand LYMPHIR access in Europe and the Middle East</p></li><li><p>Citius focuses on technology-driven platform to enhance market penetration</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025</p></li><li><p>AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetration</p></li><li><p>INTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient Programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 Net Income</p></td><td></td><td><p>-$8.20 mln</p></td><td></td></tr><tr><td><p>Q1 Basic EPS</p></td><td></td><td><p>-$0.38</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79</p></li><li><p>The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months ago</p></li></ul><p>Press Release: <span>ID:nPn7wjdcta</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL1N3Z90KS:1","article_id":"2611054152","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611054152","pubTimestamp":1770988132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Citius Pharmaceuticals reports first revenue of $3.9 mlnOverviewBiopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026Net loss for Q1 2026 was $8.2 mln, with basic EP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"Citius Pharmaceuticals报告首笔收入为390万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":0.9},"content_text":"Citius Pharmaceuticals reports first revenue of $3.9 mlnOverviewBiopharmaceutical firm reported first revenue of $3.9 mln from LYMPHIR launch in Q1 2026Net loss for Q1 2026 was $8.2 mln, with basic EPS of -$0.38Citius Oncology launched LYMPHIR for cutaneous T-cell lymphoma in December 2025OutlookCitius anticipates growth from international market expansion and oncology franchise developmentCompany plans to expand LYMPHIR access in Europe and the Middle EastCitius focuses on technology-driven platform to enhance market penetrationResult DriversLYMPHIR LAUNCH - Initial revenue of $3.9 mln generated from LYMPHIR sales after its launch in December 2025AI-ENABLED PLATFORM - Citius deployed an AI-enabled commercial platform to support LYMPHIR's market penetrationINTERNATIONAL EXPANSION - Agreements with regional partners to expand LYMPHIR access through Named Patient ProgramsKey DetailsMetricBeat/MissActualConsensus EstimateQ1 Net Income-$8.20 mlnQ1 Basic EPS-$0.38Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 530.2% above its February 12 closing price of $0.79The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 3 three months agoPress Release: ID:nPn7wjdctaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}